Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06297291 · ClinicalTrials.gov registry record

Global Paradise System US Post Approval Study

A clinical trial of Hypertension and Cardiovascular Diseases, sponsored by ReCor Medical.

Recruiting
Registry status
1,000
Enrollment target
20
Study locations

NCT06297291 is a study of Hypertension and Cardiovascular Diseases that is actively recruiting participants, run by ReCor Medical. The registered enrollment target is 1,000 participants, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06297291, a study of Hypertension and Cardiovascular Diseases, is actively recruiting participants, sponsored by ReCor Medical.

RECRUITING
Registry status
1,000 participants
Enrollment target
20
Study locations

Study Summary

The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a catheter, cable, balloon, and generator and has received FDA approval in the United States. Information collected in this study will be analyzed to better understand the long-term safety and effectiveness of treatment with the Paradise System for patients with high blood pressure.

Conditions Studied

Hypertension Cardiovascular Diseases Vascular Diseases

Interventions

  • DEVICE Paradise Ultrasound Renal Denervation Treatment

Study Locations (20)

Florida

  • The Cardiac & Vascular Institute - Gainesville
  • University of Miami Health System - Miami
  • Ascension Sacred Heart - Pensacola
  • Tampa Cardiovascular Interventions and Research - Tampa

New York

  • Albany Medical Center - Albany
  • University at Buffalo - Buffalo
  • NYU Langone Health - Bellevue Hosptial - New York
  • Columbia University Medical Center/New York Presbyterian Hospital - New York

California

  • Sutter Institute for Medical Research - Sacramento
  • UC Davis Medical Center - Sacramento

Massachusetts

  • Massachusetts General Hospital - Boston
  • The Brigham and Women's Hospital - Boston

Colorado

  • Rocky Mountain Regional VAMC - Aurora

Connecticut

  • Bridgeport Hosptial - Bridgeport

Illinois

  • Southern Illinois University, Memorial Medical Center - Springfield

Kansas

  • Ascension via Christi St. Francis - Wichita

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2024-06-28
Est. Completion 2031-07

Sponsor

ReCor Medical

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06297291

The ClinicalTrials.gov registry entry for NCT06297291 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (71% lower). The listed sponsor is ReCor Medical, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Paradise Ultrasound Renal Denervation Treatment is the first listed.

NCT06297291 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, New York, California.

Frequently Asked Questions

What is clinical trial NCT06297291 about?

NCT06297291 is a clinical study titled "Global Paradise System US Post Approval Study". The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a ...

What is the current status of trial NCT06297291?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2024-06-28. Estimated completion is 2031-07.

What conditions does trial NCT06297291 study?

This clinical trial studies the following conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases.

What interventions are being tested in trial NCT06297291?

The interventions under investigation include: Paradise Ultrasound Renal Denervation Treatment (DEVICE).

Who is sponsoring clinical trial NCT06297291?

This trial is sponsored by ReCor Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06297291 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypertension

All registered trials for this condition

Cardiovascular Diseases

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.